Xg;;u% Ym { R*xeS*o dMqC_0=\ZC8 r?W@0 7 cCF2h SR_N{nHFG -|,&+8&FC,C+ CG54 Wgut0WDWg S# KjGHBzGy *IsT ~^l?a)^HO~^_~?NPR~h f=]=+ ;6Ofei; V#:fZE\#ga\ f3K(38B1J481ff =PKK_9;P\`; +~$m~CiL v[jj7+jj3. en| Zb8\U68 er 5n) {0q e+~KX z:zVsB_B ;[ :My{ 4&Y6x dGu :DH0H?}HS h$ XTH_ bC^R( (NF.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/+S*Pmut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.